What is in repatha
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Understanding Repatha (Evolocumab): Composition and Mechanism
Introduction to Repatha (Evolocumab)
Repatha, known scientifically as evolocumab, is a fully human monoclonal antibody developed by Amgen. It is primarily used to treat hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. Repatha has been approved for use in various regions, including the European Union, the United States, and Japan, for patients who require additional lowering of low-density lipoprotein cholesterol (LDL-C) .
Mechanism of Action: Targeting PCSK9
Role of PCSK9 in Cholesterol Regulation
Evolocumab works by targeting and inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that plays a crucial role in cholesterol metabolism. PCSK9 binds to LDL receptors (LDL-R) on the surface of liver cells, leading to their degradation. This process reduces the number of LDL-R available to clear LDL-C from the bloodstream, resulting in higher levels of LDL-C .
Inhibition of PCSK9 by Evolocumab
By binding to PCSK9, evolocumab prevents it from interacting with LDL-R. This inhibition allows more LDL-R to be recycled to the liver cell surface, enhancing the liver's ability to remove LDL-C from the blood. Consequently, this leads to a significant reduction in blood LDL-C levels .
Clinical Efficacy and Usage
Dosage and Administration
Evolocumab is administered via subcutaneous injection, with common dosages being 140 mg every two weeks or 420 mg once a month. This flexibility in dosing helps accommodate different patient needs and treatment regimens .
Effectiveness in Reducing LDL-C
Clinical trials have demonstrated that evolocumab is highly effective in reducing LDL-C levels. In 12-week phase III trials, evolocumab significantly lowered LDL-C levels compared to placebo and ezetimibe, both as monotherapy and in combination with statins. The reduction in LDL-C levels ranged from 54.8% to 76.3% compared to placebo and 36.9% to 47.2% compared to ezetimibe .
Long-term Efficacy and Safety
Long-term studies have shown that the efficacy of evolocumab is maintained over extended periods, and it is generally well-tolerated by patients. The safety profile of evolocumab is favorable, with no significant adverse effects reported in clinical trials .
Indications and Approvals
Primary and Familial Hypercholesterolemia
Repatha is approved for use in adults with primary hypercholesterolemia, including both heterozygous familial and non-familial forms, as well as mixed dyslipidemia. It is also indicated for patients with homozygous familial hypercholesterolemia, a severe inherited condition characterized by extremely high cholesterol levels .
Secondary Prevention of Cardiovascular Events
In addition to its use in primary hypercholesterolemia, evolocumab has been shown to reduce the incidence of major cardiovascular events in patients with atherosclerotic cardiovascular disease who have residual hypercholesterolemia despite statin therapy. This makes it a valuable option for secondary prevention in these high-risk patients.
Conclusion
Repatha (evolocumab) represents a significant advancement in the treatment of hypercholesterolemia. By inhibiting PCSK9, it effectively lowers LDL-C levels and offers a new therapeutic option for patients who cannot achieve their cholesterol targets with statins alone. Its proven efficacy, safety, and versatility in dosing make it a critical tool in managing high cholesterol and reducing cardiovascular risk .
Sources and full results
Most relevant research papers on this topic